Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Recruitment status was Recruiting
determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|
- Citrullinemia (weekly) [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
- Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ] [ Designated as safety issue: Yes ]
|Study Start Date:||April 2008|
|Estimated Study Completion Date:||September 2009|
|Estimated Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).
Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00751452
|Contact: Lacarin Patrickfirstname.lastname@example.org|
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Merlin Etienne, Dr||University Hospital, Clermont-Ferrand|